PCSK9 and colorectal carcinoma: In this study, we investigated PCSK9 during anti-PD-1 therapy in CRC models, and PD-1 inhibitor and anti-PCSK9 antibody were administered to confirm the synergetic antitumor effect of targeting PD-1 and PCSK9 in CRC.